FDA — authorised 31 May 2018
- Application: NDA207924
- Marketing authorisation holder: ELI LILLY AND CO
- Indication: Type 1 - New Molecular Entity
- Status: approved
🇺🇸 Olumiant in United States
FDA authorised Olumiant on 31 May 2018
Marketing authorisation
Olumiant in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Olumiant approved in United States?
Yes. FDA authorised it on 31 May 2018.
Who is the marketing authorisation holder for Olumiant in United States?
ELI LILLY AND CO holds the US marketing authorisation.